TSHA

Taysha Gene Therapies, Inc.

Biotechnology · Biotechnology

$283.69 sample

+4.27 (+1.53%) 1D

Market cap

$185.5B

Price as of

2026-10-04

Latest filing

8-K · 2026-09-15

Alerts

8

Price$283.69 +11.98% 3M daily closessample

283.69244.66

2026-07-072026-07-292026-08-202026-09-102026-10-02

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Sep 29INSInsider buy: Director
Sep 24INSInsider sell: EVP, Operations
Sep 15SEC10-Q filed
Sep 10SECDEF 14A filed
Sep 04SEC8-K filed: material event
Aug 31INSInsider sell: EVP, Operations
Aug 26SEC8-K filed: material event
Aug 20INSInsider sell: Chief Financial Officer

Sign up to see the real TSHA record →

Company facts

SEC EDGAR registration

Name: Taysha Gene Therapies, Inc.
Sector: Biotechnology
Industry: Biotechnology
Smart-money score: -45sample, -100 to +100
Reporting currency: USD

Who is positioning in TSHA

sample

Insiders: 6 insider transactions over 90 days, net selling, $865.5M
Congress: 5 members traded over 90 days
Institutions · 13F: 19 funds hold $1.1B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$11.7B +10.3% y/y

Q4 2024Q3 2026

Inventory$7.1B +19.1% y/y

Q4 2024Q3 2026

Accounts receivable$5.4B +15.5% y/y

Q4 2024Q3 2026

Total debt$14.1B +11.1% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $178.3B -8.7% 3M
Sample peer B: $66.1B -4.9% 3M
Sample peer C: $84.3B +15.2% 3M
Sample peer D: $39.3B +16.3% 3M
Sample peer E: $184.7B +14.1% 3M